Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Pathways (CLPA) -- Ignore unavailable to you. Want to Upgrade?

To: Urlman who wrote (7)	11/2/1998 11:15:00 AM
From: bob	Read Replies (1) \| Respond to of 566

Urlman, NEWS TODAY!!!</> Company Press Release Cell Pathways Shareholders Approve Combination With Tseng Labs HORSHAM, Pa.--(BW HealthWire)--Nov. 2, 1998--Cell Pathways, Inc. today announced that at a Special Meeting held this morning the stockholders of Cell Pathways, Inc. approved the company's previously announced combination with Tseng Labs, Inc. (Nasdaq:TSNG - news). Assuming that the stockholders of Tseng Labs also approve the transaction at the Tseng Special Meeting tomorrow morning, and the closing occurs as expected, trading in the stock of Tseng Labs will cease at the end of the day on November 3 and trading in the stock of the new Cell Pathways (Nasdaq:CLPA - news) will commence on November 4. Based on the agreed exchange ratio for the transaction, stockholders of Tseng laboratories will receive approximately 0.36 of a share of Cell Pathways Common Stock for each share of Tseng Laboratories. Shares of Tseng Labs closed Friday at $6.875 per share. Cell Pathways, Inc. is a pharmaceutical company focused on the development and commercialization of products to prevent and treat cancer. For additional information on Cell Pathways, Inc., visit the company's Web site at cellpathways.com. -------------------------------------------------------------------------------- Contact: Cell Pathways, Inc. Robert J. Towarnicki, 215/706-3800 (CEO) --------------------------------------------------------------------

To: Urlman who wrote (7)	11/3/1998 4:48:00 PM
From: Urlman	Read Replies (2) \| Respond to of 566

The Scientist March 16, 1998 Biotech Firms On Quest For Apoptotic Therapies Cell Pathways Inc., a privately owned <sic>molecular oncology firm based in Horsham, Pa., also seeks to interfere with the apoptotic pathway by using its lead compound, FGN-1 (Ixosulin). FGN-1 induces apoptosis in precancerous tumor cells while avoiding inf lammation. The compound is a metabolic byproduct of sulindac (Clinoril), an anti-inflammatory drug used to treat arthritis. Whitehouse Station, N.J.-based Merck & Co. Inc. manufactures sulindac. Rifat Pamukcu, Cell Pathways' chief science officer, thought sulindac could also be an anti-cancer agent when he heard anecdotal reports that the compound seemed to suppress tumors in some patients. Epidemiological evidence lent credence to those reports. Studies showed that a sulfone metabolite of sulindac caused apoptosis independently of the mechanism that made the drug an effective anti-inflammatory agent (G.A. Piazza et al., Cancer Research, 57:2452-9, 1997). Cell Pathways scientists then isolated the metabolite, turned it into an anti-cancer candidate, and began clinical trials, after noting that the drug resulted in low toxicity in animal models. Results from Phase III clinical trials look promising, attests Gary A. Piazza, Cell Pathways' senior director of cell biology, who notes that FGN-1 showed signs of causing precancerous polyp regression in earlier phases of the drug's testing. the-scientist.library.upenn.edu